Another key player in China’s biotech ecosystem has landed a pharma deal. On Sunday, Eli Lilly and Insilico Medicine announced a drug discovery collaboration, with

The heart drug that Braveheart Bio licensed from China’s Jiangsu Hengrui Pharmaceuticals has shown promise in a mid-stage trial, according to data released Monday. The

Kailera Therapeutics has filed for an IPO, ​hoping to whet investor appetites with its pipeline of drug candidates for weight loss.

Sanofi on Saturday shared more mixed efficacy results from a Phase 3 atopic dermatitis program for its anti-OX40 ligand monoclonal antibody, further eroding Wall Street’s

Amgen’s fast-growing bispecific T-cell engager Imdylltra should be cleared as a second-line therapy for small cell lung cancer, said the CHMP.